Pipeline

Note: BsAb=Bispecific antibody, TsAb=Trispecific antibody 

      Pipeline Highlight as of April 2025


当前位置：
Home ⊙ Pipeline
        Core assets 

LB4330 -(CD8+ T Cells Activator) 


LB4330, targeting CD8+ T cells and CLDN18.2, is a globally pioneering dual-functional immunotherapy product developed independently by L&L Biopharma. It is intended to be used for the treatment of CLDN18.2-positive pancreatic cancer, gastric cancer, ovarian cancer, and is expected to expand to a broad spectrum of solid tumors regardless of CLDN18.2 status.


LB4330 will enrich around tumors that are positive for CLDN18.2 after administration, due to its superior binding affinity to CLDN18.2. And then its active ligands activate CD8+ cells in the tumor microenvironment, promoting CD8+ T cell proliferation and interferon secretion, killing tumor cells, and generating immune memory.


This product has obtained IND approval in China and the United States. Currently, led by Fudan University Affiliated Cancer Hospital, Phase I clinical research is underway and has entered the expansion stage. 


LB1410-(PD-1/TIM-3 BsAb)


LB1410, a PD-1/TIM-3 bispecific antibody, exerts a more  effective synergistic effect on regulating the patient's immune microenvironment by simultaneously blocking the PD-1/PD-L1 and TIM-3/ligand signaling pathways. It is expected to show efficacy in subgroups of patients with solid tumors such as lung cancer, esophageal cancer, colorectal cancer, urothelial carcinoma, and lymphoma who are resistant or unresponsive to anti-PD-1/PD-L1 antibody therapies.

LB1410 is the first domestic product targeting the same antigens to enter Phase I clinical trials, progressing globally in parallel with AstraZeneca's AZD7789. Compared to AZD7789, LB1410 demonstrates higher affinity to TIM-3 and better in vitro DC-T cell activation.

Currently, led by Shanghai Pulmonary Hospital, this product is undergoing Phase I clinical research in China and has entered the expansion phase. It has also been approved by NMPA to conduct Ib/IIa clinical trial in combination with LB4330 in China.

LB4330 enhances CD8+ T cells in tumor microenviroment
MOA of LB1410